Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07161310 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors

Study acronym: MitoCancer
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Sep 2025 to Jan 2, 2026 · Primary completion date: Nov 2026 to Jan 2027 · Completion date: Dec 2026 to Mar 2027 · 1 morev3 Show 4 more changesShow less
    • Start date changed from estimate of Sep 2025 to Jan 2, 2026
    • Primary completion date: Nov 2026 to Jan 2027
    • Completion date: Dec 2026 to Mar 2027
    • Site details revised
  2. Study title shortened, about 6 wordsv2 See this version in full on ClinicalTrials.gov ↗
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this clinical study is to learn more about the effects of urolithin A (MitoPure®) on the immune system of cancer patients receiving immune checkpoint inhibitor-based therapies. Any effects will be compared with patients who take a placebo instead of urolithin A (MitoPure®).
Trial Details
NCT Number NCT07161310
Lead Sponsor Goethe University
Collaborators: Amazentis SA, Georg-Speyer-Haus
Conditions Solid Cancer, Non-Small Cell Lung Cancer, Melanoma
Enrollment 45 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov